<unk> , sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medication consists of a humanized monoclonal antibody against CD22<unk> , linked to a cytotoxic agent from the class of calicheamicins called ozogamicin. This drug was discovered by scientists collaborating at Celltech and Wyeth, and it was developed by Pfizer which had acquired Wyeth. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Inotuzumab ozogamicin
Ranibizumab
Gemtuzumab ozogamicin
Bevacizumab
Ponatinib
Sorafenib
Ruxolitinib
Erdafitinib